Palvella Therapeutics Inc is a clinical-stage biopharmaceutical company whose vision is to become the rare disease biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare skin diseases and vascular malformations for which there are no FDA-approved therapies... Show more
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| LNGX | 40.75 | 0.82 | +2.06% |
| Global X U.S. Natural Gas ETF | |||
| ZAPR | 26.59 | -0.01 | -0.04% |
| Innovator Equity Dfnd Prt ETF -1 Yr Apr | |||
| FOCT | 52.15 | -0.08 | -0.15% |
| FT Vest US Equity Buffer ETF Oct | |||
| NPV | 11.38 | -0.03 | -0.26% |
| Nuveen Virginia Quality Municipal Income Fund | |||
| CUT | 27.80 | -0.17 | -0.62% |
| Invesco MSCI Global Timber ETF | |||
A.I.dvisor indicates that over the last year, PVLA has been loosely correlated with DRMA. These tickers have moved in lockstep 42% of the time. This A.I.-generated data suggests there is some statistical probability that if PVLA jumps, then DRMA could also see price increases.
| Ticker / NAME | Correlation To PVLA | 1D Price Change % | ||
|---|---|---|---|---|
| PVLA | 100% | +5.08% | ||
| DRMA - PVLA | 42% Loosely correlated | +5.13% | ||
| VIR - PVLA | 41% Loosely correlated | +4.48% | ||
| IOVA - PVLA | 38% Loosely correlated | +3.84% | ||
| ARQT - PVLA | 37% Loosely correlated | +1.76% | ||
| SEPN - PVLA | 35% Loosely correlated | -3.70% | ||
More | ||||
Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where PVLA advanced for three days, in of 268 cases, the price rose further within the following month. The odds of a continued upward trend are .
The Momentum Indicator moved above the 0 level on June 22, 2026. You may want to consider a long position or call options on PVLA as a result. In of 98 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .
The Moving Average Convergence Divergence (MACD) for PVLA just turned positive on June 15, 2026. Looking at past instances where PVLA's MACD turned positive, the stock continued to rise in of 36 cases over the following month. The odds of a continued upward trend are .
PVLA may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Stochastic Oscillator entered the overbought zone. Expect a price pull-back in the foreseeable future.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where PVLA declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
The Aroon Indicator for PVLA entered a downward trend on June 22, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. PVLA’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (7.337) is normal, around the industry mean (20.966). P/E Ratio (14.218) is within average values for comparable stocks, (36.007). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.690). PVLA has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.038). P/S Ratio (0.000) is also within normal values, averaging (367.026).
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. PVLA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.